Cerity Partners
BPMC

Cerity Partners’s Blueprint Medicines BPMC Stock Holding History

Cerity Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,035
Closed -$645K – 2761
2025
Q2 		$645K Buy
5,035
+407
+9% +$42.3K ﹤0.01% 1736
2025
Q1 		$410K Buy
4,628
+1,330
+40% +$130K ﹤0.01% 1878
2024
Q4 		$291K Buy
+3,298
New +$302K ﹤0.01% 2050
2024
Q2 		– Sell
-2,877
Closed -$273K – 2249
2024
Q1 		$273K Buy
+2,877
New +$247K ﹤0.01% 1917
2022
Q1 		– Sell
-2,290
Closed -$245K – 957
2021
Q4 		$245K Buy
2,290
+94
+4% +$9.83K ﹤0.01% 858
2021
Q3 		$226K Buy
+2,196
New +$204K 0.01% 625
2021
Q2 		– Sell
-2,150
Closed -$209K – 711
2021
Q1 		$209K Hold
2,150
– – 0.01% 650
2020
Q4 		$241K Buy
+2,150
New +$227K 0.01% 563

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cerity Partners's BPMC Position: Q3 2025 in Review

Cerity Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 5,035 shares — an estimated $645K sold.

Cerity Partners first reported a position in BPMC in Q4 2020 and held it in 8 quarters. The position peaked at $645K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Cerity Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Cerity Partners sold 5,035 Blueprint Medicines shares in Q3 2025, an estimated $645K.
  • Cerity Partners first reported a position in Blueprint Medicines in Q4 2020 and held it in 8 quarters.
  • Cerity Partners's Blueprint Medicines position peaked at $645K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Cerity Partners's 13F filing for Q3 2025, filed 22 Oct 2025.